Smad3 as a mediator of the fibrotic response
Top Cited Papers
- 1 April 2004
- journal article
- review article
- Published by Wiley in International Journal of Experimental Pathology
- Vol. 85 (2) , 47-64
- https://doi.org/10.1111/j.0959-9673.2004.00377.x
Abstract
Transforming growth factor-beta (TGF-beta) plays a central role in fibrosis, contributing to the influx and activation of inflammatory cells, the epithelial to mesenchymal transdifferentiation (EMT) of cells and the influx of fibroblasts and their subsequent elaboration of extracellular matrix. TGF-beta signals through transmembrane receptor serine/threonine kinases to activate novel signalling intermediates called Smad proteins, which modulate the transcription of target genes. The use of mice with a targeted deletion of Smad3, one of the two homologous proteins which signals from TGF-beta/activin, shows that most of the pro-fibrotic activities of TGF-beta are mediated by Smad3. Smad3 null inflammatory cells and fibroblasts do not respond to the chemotactic effects of TGF-beta and do not autoinduce TGF-beta. The loss of Smad3 also interferes with TGF-beta-mediated induction of EMT and genes for collagens, plasminogen activator inhibitor-1 and the tissue inhibitor of metalloprotease-1. Smad3 null mice are resistant to radiation-induced cutaneous fibrosis, bleomycin-induced pulmonary fibrosis, carbon tetrachloride-induced hepatic fibrosis as well as glomerular fibrosis induced by induction of type 1 diabetes with streptozotocin. In fibrotic conditions that are induced by EMT, such as proliferative vitreoretinopathy, ocular capsule injury and glomerulosclerosis resulting from unilateral ureteral obstruction, Smad3 null mice also show an abrogated fibrotic response. Animal models of scleroderma, cystic fibrosis and cirrhosis implicate involvement of Smad3 in the observed fibrosis. Additionally, inhibition of Smad3 by overexpression of the inhibitory Smad7 protein or by treatment with the small molecule, halofuginone, dramatically reduces responses in animal models of kidney, lung, liver and radiation-induced fibrosis. Small moleucule inhibitors of Smad3 may have tremendous clinical potential in the treatment of pathological fibrotic diseases.Keywords
This publication has 114 references indexed in Scilit:
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Sustained Activation of Fibroblast Transforming Growth Factor-β/Smad Signaling in a Murine Model of SclerodermaJournal of Investigative Dermatology, 2003
- Cross‐talk between ERK MAP kinase and Smad‐signaling pathways enhances TGF‐β dependent responses in human mesangial cellsThe FASEB Journal, 2003
- Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-β-induced fibronectin in mesangial cellsBiochemical and Biophysical Research Communications, 2002
- TGF-β signaling: positive and negative effects on tumorigenesisCurrent Opinion in Genetics & Development, 2002
- Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesisCurrent Opinion in Rheumatology, 2001
- Transforming Growth Factor-β Repression of Matrix Metalloproteinase-1 in Dermal Fibroblasts Involves Smad3Journal of Biological Chemistry, 2001
- Differential Expression of Transforming Growth Factor-β Receptors I and II and Activation of Smad 3 in Keloid FibroblastsPlastic and Reconstructive Surgery, 2001
- Sp1 and Smad Proteins Cooperate to Mediate Transforming Growth Factor-β1-induced α2(I) Collagen Expression in Human Glomerular Mesangial CellsPublished by Elsevier ,2001
- Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivatorsOncogene, 2000